nach oben

Erschienen in:

14.08.2017 | Original Article

Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Hu-antigen R (HuR), a RNA-binding protein, is considered to play a crucial role in tumor development and progression by stabilizing or regulating a group of cellular mRNAs of cancer-related genes, such as cyclooxygenase-2 (COX-2). The present study aimed to evaluate the clinical significance of HuR and COX-2 expression in invasive breast carcinoma. HuR and COX-2 protein expression was assessed immunohistochemically on paraffin-embedded breast cancer tissue sections obtained from 121 patients and was statistically analyzed with clinicopathological parameters, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as with tumor cells’ proliferative capacity and overall and disease-free patients’ survival. High HuR expression was positively associated with larger tumor size and advanced disease stage (p = 0.0234 and p = 0.0361, respectively), being more frequently observed in ER negative cases (p = 0.0208). High COX-2 expression was negatively associated with histological (p < 0.0001) and nuclear (p = 0.0033) grade and tumor cells’ proliferative rate (p = 0.0015), being more frequently observed in luminal-A compared to other molecular subtypes (p = 0.0221). High HuR expression was associated with poor overall and disease-free patients’ survival at both univariate (log-rank test, p = 0.0092 and p = 0.0004, respectively) and multivariate (Cox-regression analysis, p = 0.0223 and p = 0.0004, respectively) level. On the other hand, high COX-2 expression was associated with favorable overall and disease-free patients’ survival merely at univariate level (log-rank test, p = 0.0389 and p = 0.0154, respectively). HuR expression was not associated with COX-2 expression (Spearman R = 0.1489, p = 0.1032). The present data support evidence that HuR is associated with tumor aggressiveness and poor prognosis in breast carcinoma, reinforcing its potential as promising therapeutic target in this type of neoplasia.

Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H (1996) Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 271:8144–81451CrossRefPubMed

Burd CG, Dreyfuss G (1994) Conserved structures and diversity of functions of RNA-binding proteins. Science 265:615–621CrossRefPubMed

Lopez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M (2004) Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A 101:2987–2992CrossRefPubMed

Brennan CM, Steitz JA (2001) HuR and mRNA stability. Cell Mol Life Sci 58:266–277CrossRefPubMed

Kullmann M, Gopfert U, Siewe B, Hengst L (2002) ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5'UTR. Genes Dev 16:3087–3099CrossRefPubMedPubMedCentral

Mazan-Mamczarz K, Galban S, Lopez de Silanes I et al (2003) RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci U S A 100:8354–8359CrossRefPubMedPubMedCentral

Zhu H, Zhou HL, Hasman RA, Lou H (2007) Hu proteins regulate polyadenylation by blocking sites containing U-rich sequences. J Biol Chem 282:2203–2210CrossRefPubMed

Fan XC, Steitz JA (1998) HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci U S A 95:15293–11528CrossRefPubMedPubMedCentral

Keene JD (1999) Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. Proc Natl Acad Sci U S A 96:5–7CrossRefPubMedPubMedCentral

10.

Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS (2011) Biology of COX-2: an application in cancer therapeutics. Curr Drug Targets 12:1082–1093CrossRefPubMed

11.

Ghosh N, Chaki R, Mandal V, Mandal SC (2010) COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62:233–244CrossRefPubMed

12.

Skibinski A, Kuperwasser C (2015) The origin of breast tumor heterogeneity. Oncogene 34:5309–5316CrossRefPubMedPubMedCentral

13.

Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W (2016) Molecular imaging of biomarkers in breast cancer. J Nucl Med 57:53S–59SCrossRefPubMedPubMedCentral

14.

Kos Z, Dabbs DJ (2016) Biomarker assessment and molecular testing for prognostication in breast cancer. Histopathology 68:70–85CrossRefPubMed

15.

Kotta-Loizou I, Giaginis C, Theocharis S (2014) Clinical significance of HuR expression in human malignancy. Med Oncol 31:161CrossRefPubMed

16.

Rhee WJ, Ni CW, Zheng Z, Chang K, Jo H, Bao G (2010) HuR regulates the expression of stress-sensitive genes and mediates inflammatory response in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A 107:6858–6863CrossRefPubMedPubMedCentral

17.

Zhang J, Modi Y, Yarovinsky T et al (2012) Macrophage beta2 integrin-mediated, HuR-dependent stabilization of angiogenic factor-encoding mRNAs in inflammatory angiogenesis. Am J Pathol 180:1751–1760CrossRefPubMedPubMedCentral

18.

Lopez de Silanes I, Lal A, Gorospe M (2005) HuR: post-transcriptional paths to malignancy. RNA Biol 2:11–13CrossRefPubMed

19.

Giaginis C, Alexandrou P, Tsoukalas N et al (2015) Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. Tumour Biol 36:315–327CrossRefPubMed

20.

Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M (2008) miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci U S A 105:20297–20302CrossRefPubMedPubMedCentral

21.

Abdelmohsen K, Kim MM, Srikantan S et al (2010) miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 9:1354–1359CrossRefPubMedPubMedCentral

22.

Srikantan S, Gorospe M (2012) HuR function in disease. Front Biosci (Landmark Ed) 17:189–205CrossRef

23.

Saunus JM, French JD, Edwards SL et al (2008) Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res 68:9469–9478CrossRefPubMed

24.

Denkert C, Weichert W, Winzer KJ et al (2004) Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 10:5580–5586CrossRefPubMed

25.

Heinonen M, Hemmes A, Salmenkivi K et al (2011) Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol 224:529–539CrossRefPubMedPubMedCentral

26.

Zhu Z, Wang B, Bi J et al (2013) Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol 34:2299–2308CrossRefPubMed

27.

Wang J, Li D, Wang B, Wu Y (2013) Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 141:213–224CrossRefPubMed

28.

Heinonen M, Bono P, Narko K et al (2005) Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 65:2157–2161CrossRefPubMed

29.

Heinonen M, Fagerholm R, Aaltonen K et al (2007) Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res 13:6959–6963CrossRefPubMed

30.

Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG (2011) Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. Anticancer Res 31:303–310PubMed

31.

Ortega AD, Sala S, Espinosa E, Gonzalez-Baron M, Cuezva JM (2008) HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis 29:2053–2061CrossRefPubMed

32.

Tavassoli FA, Devilee P (eds) (2003) Pathology and genetics tumors of the breast and female genital organs. IARC WHO classification of tumors, no. 4. WHO Press, Lyon, pp 25–27

33.

Hermanek P, Sabin H (eds) (1992) TNM classification of international union against cancer. In TNM atlas, 3rd rev, 4th edn. Springer-Verlag, Berlin, pp 15–25

34.

Robins P, Pinder S, de Klerk N (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 6:873–879CrossRef

35.

Mylona E, Vamvakaris I, Giannopoulou I et al (2013) An immunohistochemical evaluation of the proteins Wnt1 and glycogen synthase kinase (GSK)-3β in invasive breast carcinomas. Histopathology 62:899–907CrossRefPubMed

36.

Michailidi C, Giaginis C, Stolakis V et al (2010) Evaluation of FAK and Src expression in human benign and malignant thyroid lesions. Pathol Oncol Res 16:497–507CrossRefPubMed

37.

Giaginis C, Alexandrou P, Delladetsima I, Giannopoulou I, Patsouris E, Theocharis S (2014) Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol 35:61–71CrossRefPubMed

38.

Mylona E, Melissaris S, Nomikos A et al (2014) Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas. Pathol Res Pract 210:533–540CrossRefPubMed

39.

Giaginis C, Alexandrou P, Delladetsima I et al (2016) Clinical significance of Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human malignant and benign thyroid lesions. Pathol Oncol Res 22:189–196CrossRefPubMed

40.

Hammond MEH, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2786–2795CrossRef

41.

Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–3401CrossRefPubMed

42.

Nakopoulou L, Mylona E, Papadaki I et al (2005) Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology 72:241–249CrossRefPubMed

Titel: Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients
Publikationsdatum: 14.08.2017
Erschienen in: Pathology & Oncology Research / Ausgabe 3/2018
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-017-0288-1

Springer Medizin

Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors

Distribution of Vascular Patterns in Different Subtypes of Renal Cell Carcinoma. A Morphometric Study in Two Distinct Types of Blood Vessels

Frameshift Mutations in Repeat Sequences of ANK3, HACD4, TCP10L, TP53BP1, MFN1, LCMT2, RNMT, TRMT6, METTL8 and METTL16 Genes in Colon Cancers

Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study

Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps

High- and low-Molecular Weight oat Beta-Glucan Reveals Antitumor Activity in Human Epithelial Lung Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie